NRC Health Posts Mixed Q2 2026: TRCV Growth Contrasts with GAAP Loss
Event summary
- TRCV grew 11% YoY to $151.9M, while revenue rose 4% to $35.4M.
- GAAP net loss was $(3.3)M (9% of revenue), but adjusted net income was $6.9M (19% of revenue).
- The Governance Institute saw its strongest bookings performance in seven years.
- Dividend declared at $0.16 per share, payable October 9, 2026.
The big picture
NRC Health’s Q2 results highlight a strategic tension between recurring contract value growth and GAAP profitability challenges. The company is positioning itself as a key partner for healthcare organizations seeking to improve experience outcomes, but its ability to balance cost management with innovation will be critical in the second half of 2026.
What we're watching
- Execution Risk
- Whether NRC Health can sustain TRCV growth amid rising operating expenses.
- Governance Dynamics
- The impact of The Governance Institute’s strong bookings on future revenue streams.
- Cash Flow Trends
- How free cash flow will evolve given the $2.9M adjustment-related payment in Q2.
Related topics